Table 3. Univariate and multivariate analysis of prognostic factors for progression-free survival.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Sex (male vs. female) | 1.692 (0.943–3.038) | 0.078 | ||
| Age (> 7 years vs. ≤ 7 years) | 1.563 (0.862–2.837) | 0.142 | ||
| Previous chemotherapy (yes vs. no) | 2.711 (1.159–6.343) | 0.021 | 8.371 (2.968- 23.613) | < 0.001 |
| Stage (V vs. II+III+IV) | 2.746 (1.267–5.954) | 0.011 | 2.242 (0.982–5.119) | 0.055 |
| Systemic signs (b vs. a) | 1.266 (0.711–2.257) | 0.423 | ||
| Immunophenotype (T vs. B) | 2.198 (0.931–5.190) | 0.072 | ||
| Morphotype (DLBCL vs. others) | 0.362 (0.185–0.709) | 0.003 | 0.289 (0.142–0.586) | 0.001 |
| Pgp (Pgp+ vs. Pgp-) | 0.631 (0.335–1.190) | 0.155 | ||
| D-dimer level (> 0.5 vs. ≤ 0.5 μg/mL) | 2.218 (1.175–4.187) | 0.014 | 3.197 (1.536–6.655) | 0.002 |
| Treatment group (F14512 vs. Etoposide) | 0.732 (0.403–1.332) | 0.307 | ||
DLBCL: Diffuse large B-cell lymphoma, Pgp: P-glycoprotein.